The CLSN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CLSN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The CLSN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View CLSN Detailed Price Forecast - CNN Money||View CLSN Detailed Summary - Google Finance|
|View CLSN Detailed Summary - Yahoo! Finance||View CLSN Stock Research & Analysis - Zacks.com|
|View CLSN Trends & Analysis - Trade-Ideas||View CLSN Major Holders - Barrons|
|View CLSN Call Transcripts - NASDAQ||View CLSN Breaking News & Analysis - Seeking Alpha|
|View CLSN Annual Report - CompanySpotlight.com||View CLSN OTC Short Report - OTCShortReport.com|
|View CLSN Fundamentals - TradeKing||View CLSN SEC Filings - Bar Chart|
|View Historical Prices for CLSN - The WSJ||View Performance/Total Return for CLSN - Morningstar|
|View the Analyst Estimates for CLSN - MarketWatch||View the Earnings History for CLSN - CNBC|
|View the CLSN Earnings - StockMarketWatch||View CLSN Buy or Sell Recommendations - MacroAxis|
|View the CLSN Bullish Patterns - American Bulls||View CLSN Short Pain Metrics - ShortPainBot.com|
|View CLSN Stock Mentions - StockTwits||View CLSN Stock Mentions - PennyStockTweets|
|View CLSN Stock Mentions - Twitter||View CLSN Investment Forum News - Investor Hub|
|View CLSN Stock Mentions - Yahoo! Message Board||View CLSN Stock Mentions - Seeking Alpha|
|View Insider Transactions for CLSN - SECform4.com||View Insider Transactions for CLSN - Insider Cow|
|View CLSN Major Holdings Summary - CNBC||View Insider Disclosure for CLSN - OTC Markets|
|View Insider Transactions for CLSN - Yahoo! Finance||View Institutional Holdings for CLSN - NASDAQ|
|View CLSN Stock Insight & Charts - FinViz.com||View CLSN Investment Charts - StockCharts.com|
|View CLSN Stock Overview & Charts - BarChart||View CLSN User Generated Charts - Trading View|
Celsion Corporation to Hold Third Quarter 2018 Financial Results Conference Call on Thursday, November 15, 2018
Posted on Thursday November 08, 2018
LAWRENCEVILLE, N.J, Nov. 08, 2018 -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the.
Report: Exploring Fundamental Drivers Behind The ExOne, Switch, Monotype Imaging, Celsion, TrueCar, and Sandstorm Gold — New Horizons, Emerging Trends, and Upcoming Developments
Posted on Thursday October 25, 2018
NEW YORK, Oct. 25, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Celsion Announces Progression-Free Survival Data From GEN-1 Phase I Immuno-Oncology Study of Patients with Stage III/IV Ovarian Cancer
Posted on Wednesday October 24, 2018
Median progression-free survival (PFS) in patients treated per protocol (n=13) was 24.3 months and was 17.1 months for the intent-to-treat population (n=18) for all dose cohorts, including three patients who dropped out of the study after 13 days or less, and two patients who did not receive full neoadjuvant chemotherapy (NAC) and GEN-1 cycles. The results from the OVATION I Study support continued evaluation of GEN-1 based on promising tumor response, as reported in the PFS data, and the ability for surgeons to completely remove visible tumor at debulking surgery.
Celsion Announces Publication Highlighting the Potential of Celsion's Gene-Mediated Immunotherapy to Improve Administration of IL-12 and Progression-Free Survival in Ovarian Cancer Patients
Posted on Monday October 22, 2018
Celsion Corporation (CLSN), an oncology drug development company, today announced that a program overview of the Company’s novel, immunotherapy agent GEN-1 was published in the peer-reviewed journal, Future Oncology. The article is co-authored by Premal H. Thaker, M.D., M.S., associate professor of obstetrics and gynecology at the Siteman Cancer Center at the Washington University School of Medicine in St. Louis, Mo. and principal investigator in Celsion’s GEN-1 development program. The publication outlines the DNA plasmid, gene-based concept and the key attributes supporting GEN-1’s mechanism of action characterized by local and persistent delivery of IL-12 and modulation of tumor microenvironment favoring immune stimulation.